Diagnose and treat constipation- or diarrhoea-predominant irritable bowel syndrome with confidence

被引：0
|
作者：
Fenton, Caroline [1 ]
Kang, Connie [1 ]
机构：
[1] Springer Nat, Private Bag 65901, Auckland 0754, New Zealand
来源：
DRUGS & THERAPY PERSPECTIVES | 2022年 / 38卷 / 04期
关键词：
MANAGEMENT; GUIDELINE;
D O I：
10.1007/s40267-022-00906-w
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
Irritable bowel syndrome (IBS) is diagnosed based on clinical criteria of regular abdominal pain and disordered defaecation. If first-line treatments such as lifestyle changes fail, patients with diarrhoea-predominant IBS may respond to rifaximin, eluxadoline or, for women, alosetron, if tolerated. For constipation-predominant IBS, options are tegaserod for younger women, and the secretagogues linaclotide, plecanatide, lubiprostone and tenapanor. As IBS is a gut-brain interaction disorder, neuromodulators such as tricyclic antidepressants may help.
引用
收藏
页码：171 / 176
页数：6
相关论文
共 50 条
  • [31] BILE ACID DIARRHOEA MASQUERADES AS DIARRHOEA-PREDOMINANT IRRITABLE BOWEL SYNDROME: RESULTS FROM A DUAL CENTRE PROSPECTIVE STUDY
    Aziz, I.
    Mumtaz, S.
    Bholah, H.
    Chowdhury, F. U.
    Sanders, D. S.
    Ford, A. C.
    GUT, 2014, 63 : A257 - A258
  • [32] Bile Acid Diarrhoea Masquerades As Diarrhoea-Predominant Irritable Bowel Syndrome: Results From a Dual Centre Prospective Study
    Aziz, Imran
    Mumtaz, Saqib
    Bholah, Hassan
    Chowdhury, Fahmid U.
    Sanders, David S.
    Ford, Alexander C.
    GASTROENTEROLOGY, 2014, 146 (05) : S539 - S540
  • [33] Diarrhoea-predominant irritable bowel syndrome distinguishable by 16S rRNA gene phylotype quantification
    Lyra, Anna
    Rinttila, Teemu
    Nikkila, Janne
    Krogius-Kurikka, Lotta
    Kajander, Kajsa
    Malinen, Erja
    Matto, Jaana
    Makela, Laura
    Palva, Airi
    WORLD JOURNAL OF GASTROENTEROLOGY, 2009, 15 (47) : 5936 - 5945
  • [34] Similar pharmacokinetics of Tegaserod (HTF 919) in patients with constipation- and diarrhea-predominant irritable bowel syndrome.
    Appel-Dingemanse, S
    Rawls, J
    Heggland, J
    Campestrini, J
    Séchaud, R
    GASTROENTEROLOGY, 2000, 118 (04) : A1160 - A1160
  • [35] Gabapentin reduces rectal mechanosensitivity and increases rectal compliance in patients with diarrhoea-predominant irritable bowel syndrome
    Lee, KJ
    Kim, JH
    Cho, SW
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2005, 22 (10) : 981 - 988
  • [36] Efficacy and safety of Ayurvedic herbs in diarrhoea-predominant irritable bowel syndrome: A randomised controlled crossover trial
    Lauche, Romy
    Kumar, Syal
    Hallmann, Julia
    Luedtke, Rainer
    Rampp, Thomas
    Dobos, Gustav
    Langhorst, Jost
    COMPLEMENTARY THERAPIES IN MEDICINE, 2016, 26 : 171 - 177
  • [37] Diarrhoea-predominant irritable bowel syndrome distinguishable by 16S rRNA gene phylotype quantification
    Anna Lyra
    Teemu Rinttil
    Janne Nikkil
    Lotta Krogius-Kurikka
    Kajsa Kajander
    Erja Malinen
    Jaana Mtt
    Laura Mkel
    Airi Palva
    World Journal of Gastroenterology, 2009, 15 (47) : 5936 - 5945
  • [38] Involvement of mucosal flora and enterochromaffin cells of the caecum and descending colon in diarrhoea-predominant irritable bowel syndrome
    Jingze Yang
    Peng Wang
    Tong Liu
    Lin Lin
    Lixiang Li
    Guanjun Kou
    Ruchen Zhou
    Pan Li
    Yanqing Li
    BMC Microbiology, 21
  • [39] Long-term efficacy and safety of sacral neuromodulation for diarrhoea-predominant and mixed irritable bowel syndrome
    Fassov, J.
    Hoyer, K. L.
    Lundby, L.
    Laurberg, S.
    Scott, S. M.
    Krogh, K.
    TECHNIQUES IN COLOPROCTOLOGY, 2025, 29 (01)
  • [40] Biofeedback therapy is as effective for non-diarrhoea predominant irritable bowel syndrome as for functional constipation
    Suttor, V. P.
    Prott, G.
    Hansen, R.
    Kellow, J. E.
    Malcolm, A.
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2006, 21 : A336 - A336
12345